Comprehensive exploration of the role of multimodal programmed cell death- associated lncRNAs in the prognosis and immunity of glioma
By
Shuaishuai Wu
Xiangji Meng
Yanran Hu
Qi Wang
Yanfen Yao
Haiyan Jia
Zhen Ma
Yang Liu
Zhongxu Sun
Yahu Bai
Haixia Jin
Lingzhi Li
Changli Wang
May 14, 2026
Clinical Scorecard: In-depth Analysis of the Impact of Multimodal Programmed Cell Death-Related lncRNAs on Glioma Prognosis and Immune Response
At a Glance
Category Detail
Condition Key Mechanisms Programmed cell death (PCD) pathways including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagy. Target Population Care Setting
Key Highlights
Establishment of a PCD-associated lncRNA prognostic framework. Identification of AC092718.4 as a critical molecule affecting glioma cell behavior. Demonstrated impact of PCD pathways on glioma progression and treatment resistance. Emphasis on the role of lncRNAs in regulating PCD in CNS tumors. Potential for targeted therapies based on PCD mechanisms. Highlight the implications of PCD pathways on treatment resistance. Guideline-Based Recommendations
Diagnosis
Management
Explore innovative therapeutic approaches targeting PCD pathways, such as tyrosine kinase inhibitors and agents promoting ferroptosis. Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with glioma and related CNS tumors.
Targeting PCD pathways may enhance therapeutic efficacy and patient survival.
Clinical Best Practices
Adopt a multimodal approach to understand the interplay of various PCD pathways. Incorporate bioinformatics assessments in prognostic evaluations. Focus on the development of targeted therapies informed by PCD mechanisms. Understand the interplay of PCD pathways in treatment resistance. Related Resources & Content
